The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae

[1]  M. Herrmann,et al.  Neutrophil Extracellular Traps Tied to Rheumatoid Arthritis: Points to Ponder , 2021, Frontiers in Immunology.

[2]  M. Díaz-Ricart,et al.  Response to Maccio et al, “Multifactorial pathogenesis of COVID‐19‐related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?” , 2020, Journal of Thrombosis and Haemostasis.

[3]  C. Madeddu,et al.  Multifactorial pathogenesis of COVID‐19‐related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders? , 2020, Journal of Thrombosis and Haemostasis.

[4]  M. Díaz-Ricart,et al.  Defibrotide inhibits donor leucocyte‐endothelial interactions and protects against acute graft‐versus‐host disease , 2020, Journal of cellular and molecular medicine.

[5]  Kevin Grimes,et al.  p38 MAPK inhibition: A promising therapeutic approach for COVID-19 , 2020, Journal of Molecular and Cellular Cardiology.

[6]  V. Sheehan,et al.  The Vaso-Occlusive Pain Crisis in Sickle Cell Disease: Definition, Pathophysiology, and Management. , 2020, European journal of haematology.

[7]  Han-Hsuan Fu,et al.  Defibrotide modulates pulmonary endothelial cell activation and protects against lung inflammation in pre-clinical models of LPS-induced lung injury and idiopathic pneumonia syndrome , 2020, Frontiers in Immunology.

[8]  M. Díaz-Ricart,et al.  Up‐regulation of HDACs, a harbinger of uraemic endothelial dysfunction, is prevented by defibrotide , 2019, Journal of cellular and molecular medicine.

[9]  M. Díaz-Ricart,et al.  Acute Graft-vs.-Host Disease-Associated Endothelial Activation in vitro Is Prevented by Defibrotide , 2019, Front. Immunol..

[10]  G. Nishanth,et al.  Blood-Brain Barrier in Cerebral Malaria: Pathogenesis and Therapeutic Intervention. , 2019, Trends in parasitology.

[11]  A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity , 2019, Case Medical Research.

[12]  J. Belsey,et al.  Cost-Effectiveness of Defibrotide for the Treatment of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) with Multi-Organ Dysfunction (MOD) Post-Hematopoietic Stem Cell Transplantation (HSCT) in Canada , 2018, Blood.

[13]  H. Pass,et al.  Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications , 2018, Journal of the National Cancer Institute.

[14]  P. Richardson,et al.  The use of defibrotide in blood and marrow transplantation. , 2018, Blood advances.

[15]  P. Richardson,et al.  Final results from a defibrotide treatment‐IND study for patients with hepatic veno‐occlusive disease/sinusoidal obstruction syndrome , 2018, British journal of haematology.

[16]  M. Wurfel,et al.  Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. , 2017, Cancer discovery.

[17]  D. Markovitz,et al.  DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis , 2017, Nature Communications.

[18]  A. Gennery,et al.  Use of defibrotide to treat transplant-associated thrombotic microangiopathy: a retrospective study of the Paediatric Diseases and Inborn Errors Working Parties of the European Society of Blood and Marrow Transplantation , 2017, Bone Marrow Transplantation.

[19]  K. Horibe,et al.  Pharmacokinetics and Safety of Defibrotide in Healthy Japanese Subjects , 2016, Clinical pharmacology in drug development.

[20]  M. Díaz-Ricart,et al.  What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance. , 2016, Blood.

[21]  R. D'Agostino,et al.  Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. , 2016, Blood.

[22]  S. Giralt,et al.  Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  H. Batgi,et al.  Does defibrotide prophylaxis decrease the risk of acute graft versus host disease following allogeneic hematopoietic cell transplantation? , 2016, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[24]  M. Abecassis,et al.  Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT) , 2015, Bone Marrow Transplantation.

[25]  J. Crawford,et al.  Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). , 2014, Journal of Clinical and Experimental Hepatology.

[26]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[27]  S. Grupp,et al.  Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.

[28]  A. Fulgenzi,et al.  Defibrotide: properties and clinical use of an old/new drug. , 2013, Vascular pharmacology.

[29]  A. Schulz,et al.  Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial , 2012, The Lancet.

[30]  R. Schwarz,et al.  Defibrotide Interferes With Several Steps of the Coagulation-Inflammation Cycle and Exhibits Therapeutic Potential to Treat Severe Malaria , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[31]  M. Díaz-Ricart,et al.  Combining allografting with mTOR inhibitors for metastatic renal cell cancer , 2011, Bone Marrow Transplantation.

[32]  M. Sweet,et al.  Histone deacetylases as regulators of inflammation and immunity. , 2011, Trends in immunology.

[33]  M. Díaz-Ricart,et al.  Defibrotide prevents the activation of macrovascular and microvascular endothelia caused by soluble factors released to blood by autologous hematopoietic stem cell transplantation. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[34]  Allen R. Chen,et al.  Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[35]  A. Nagler,et al.  Genetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation: effect of discrepancy between recipients and donors. , 2010, Blood.

[36]  G. Wang,et al.  Histone Deacetylase 3 Is Critical in Endothelial Survival and Atherosclerosis Development in Response to Disturbed Flow , 2010, Circulation.

[37]  P. Richardson,et al.  The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity , 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[38]  M. Iacobelli,et al.  Prolonged Administration of Defibrotide Is Non-Immunogenic in Rats and Dogs. , 2009 .

[39]  K. Anderson,et al.  Preclinical Studies in Support of Defibrotide for the Treatment of Multiple Myeloma and Other Neoplasias , 2009, Clinical Cancer Research.

[40]  P. Richardson,et al.  Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. , 2008, Blood.

[41]  W. Aird.  Endothelium in health and disease. , 2008, Pharmacological reports : PR.

[42]  G. Koehl,et al.  Defibrotide: An endothelium protecting and stabilizing drug, has an anti-angiogenic potential in vitro and in vivo , 2007, Cancer biology & therapy.

[43]  O. Wendler,et al.  Expression and function of laminins in the embryonic and mature vasculature. , 2005, Physiological reviews.

[44]  K. Schrör,et al.  Selective stimulation of coronary vascular PGI2 but not of platelet thromboxane formation by defibrotide in the platelet perfused heart , 1985, Naunyn-Schmiedeberg's Archives of Pharmacology.

[45]  C. Legnani,et al.  Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man , 2004, European Journal of Clinical Pharmacology.

[46]  T. Barbui,et al.  Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells , 2003, Leukemia.

[47]  D. Perry,et al.  Veno-occlusive disease: cytokines, genetics, and haemostasis. , 2003, Blood reviews.

[48]  J. Chang,et al.  Role of Plasminogen Activator Inhibitor-1 (PAI-1) Levels in the Diagnosis of BMT-associated Hepatic Veno-occlusive Disease and Monitoring of Subsequent Therapy with Defibrotide (DF) , 2003, Hematology.

[49]  Allen R. Chen,et al.  Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. , 2002, Blood.

[50]  S. Kirchner,et al.  Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. , 2002, Blood.

[51]  D. Hoppensteadt,et al.  Tissue Factor Pathway Inhibitor Release Induced by Defibrotide and Heparins , 2001, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[52]  S. Friedman.  Molecular Regulation of Hepatic Fibrosis, an Integrated Cellular Response to Tissue Injury* , 2000, The Journal of Biological Chemistry.

[53]  D. Neuberg,et al.  Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. , 1998, Blood.

[54]  B. Hunt,et al.  Endothelial cell activation , 1998, BMJ.

[55]  W. Wilmanns,et al.  Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. , 1997, Blood.

[56]  B. Campbell,et al.  Effects of defibrotide on leukocyte-endothelial cell interaction in the rat mesenteric vascular bed: role of P-selectin. , 1996, Methods and findings in experimental and clinical pharmacology.

[57]  S. Chierchia,et al.  Drug‐induced in vitro inhibition of neutrophil‐endothelial cell adhesion , 1996, British journal of pharmacology.

[58]  G. Maurer,et al.  Thrombolytic Therapy in Acute Myocardial Infarction , 1996, Seminars in thrombosis and hemostasis.

[59]  F. Pasini,et al.  Modulation of venous endothelial activity and transcellular calcium transport by defibrotide: the adenosine hypothesis. , 1996, Seminars in thrombosis and hemostasis.

[60]  S. Bearman,et al.  The syndrome of hepatic veno-occlusive disease after marrow transplantation. , 1995, Blood.

[61]  K. Schrör,et al.  Isolation and identification of aptamers from defibrotide that act as thrombin antagonists in vitro. , 1994, Biochemical and biophysical research communications.

[62]  Quansheng Zhou,et al.  Defibrotide Stimulates Expression of Thrombomodulin in Human Endothelial Cells , 1994, Thrombosis and Haemostasis.

[63]  K. Goa,et al.  Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. , 1993, Drugs.